A. Marabelle

OncoDaily

News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary

Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me

April, 2025

A. Marabelle

Feb 20, 2025, 10:45 | Blog

Evaluating molecularly guided therapies beyond tumor type - ESMO

ESMO shared a post on X: "The ESMO Tumor-Agnostic Classifier and Screener (ETAC-S) introduces a…

Oct 27, 2024, 19:53 | Blog

Andre Fabrice: ESMO Tumor Agnostic Classifier and Screener

Andre Fabrice, Director of the Research Division at Gustave Roussy Cancers Center, shared on X:…

Sep 1, 2024, 16:52 | Blog

Paolo Cotzia about the ESMO Tumor-Agnostic Classifier taxonomy

Paolo Cotzia shared a post on LinkedIn about recently published paper: The ESMO Tumour-Agnostic Classifier…

Aug 27, 2024, 23:09 | Blog

Juliana Beal: Our ETAC-S paper was published in Annals of Oncology

Juliana Beal, Medical oncologist at Hospital Israelita Albert Einstein, shared on X: "So I just got…

May 24, 2024, 11:17 | Insight

Piotr Wysocki: Patients with hypermutated colorectal cancer (POLE/D1pd) derive profound benefit from immunotherapy

Piotr Wysocki recently posted on LinkedIn: "Ambrosini N et al. published online (Annals of Oncology) the…

All: 5 Posts: 1 - 100

'

Karen Knudsen has been appointed as the CEO of the Parker Institute for Cancer Immunotherapy

'

Highlights from ELCC 2025

'

FDA Approved Pluvicto (177Lu-PSMA-617) for Metastatic Castration-Resistant Prostate Cancer

'

Meet the New AACR Board of Directores for 2025-2028 Term

'

Do Artificial Sweeteners Cause Cancer? Myths and Facts

Special Coverage

Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
ESMO 2024 Congress
September 13-17, 2024
ASCO Annual Meeting
May 30 - June 4, 2024
Yvonne Award 2024
May 31, 2024
OncoThon 2024, Online
Feb. 15, 2024
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023